Prazosin
Chronic Hepatitis C Virus Infection
Explore 3 assets in Chronic Hepatitis C Virus Infection →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
French National Agency for Research on AIDS and Viral Hepatitis
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Hepatitis C Virus Infection
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Prazosin (this asset) | French National Agency for Research on AIDS and Viral Hepatitis | P2 | B · 57 |
| Ombitasvir | Ain Shams University | P3 | A |
| Veruprevir | Ain Shams University | P3 | A |
| Dasabuvir | AbbVie | P3 | A |
| Ribavirin | Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. | P4 | A |
| Pegyinterferon-Alfa-2A | Hoffmann-La Roche | P4 | A |
| Sofosbuvir | Peking University First Hospital | P4 | A |
| Pibrentasvir | Kirby Institute | P3 | A |
| Glecaprevir | Kirby Institute | P3 | A |
+42 more in the Chronic Hepatitis C Virus Infection cohort
Other indications for Prazosin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Portal Hypertension | — | P4 | BB · 65 |
| Dementia | — | P4 | B · 62 |
| Cirrhosis Of Liver | — | P4 | B · 62 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Prazosin in Chronic Hepatitis C Virus Infection. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/prazosin-chronic-hepatitis-c-virus-infection
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →